Die wichtigsten Arbeiten zu.....
Efavirenz/Tenofovir/Emtricitabin (Atripla®)
San Francisco, 18. 2. 2010
#58LB Single-tablet, Fixed-dose Regimen of Elvitegravir/Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Achieves a High Rate of Virologic Suppression and GS-9350 Is an Effective Booster
Calvin Cohen*1, D Shamblaw2, P Ruane3, R
Elion4, E DeJesus5, H Liu6, L Zhong6,
D Warren6, B Kearney6, and S Chuck6
1Community Res Initiative of New England, Boston, MA, US; 2San
Diego, CA, US; 3Los Angeles, CA, US; 4Whitman Walker
Clin, Washington, DC, US; 5Orlando Immunology Ctr, FL, US; and 6Gilead
Sci, Foster City, CA, US
David Bangsberg*1, K Ragland2, A Monk2,
and S Deeks2
1Massachusetts Gen Hosp, Harvard Med Sch, Boston, US and 2Univ
of California, San Francisco, US
Kollegen Fragen
Diese Seite weiter empfehlen
